Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taro Pharmaceutical Industries, a multinational, science-based pharmaceutical company, has received approval from the FDA for its abbreviated new drug application for levetiracetam oral solution, 100mg/ml.
Subscribe to our email newsletter
Taro’s levetiracetam oral solution is a prescription medication used as an adjunctive therapy in the treatment of partial onset seizures in individuals with epilepsy. This new Taro product is bioequivalent to UCB’s Keppra oral solution, 100mg/ml.